Past Coverage of ACR 2014Past Coverage of ACR 2014 Return To RheumReports Home

 

Triple the Therapy, Triple the Savings?

November 18 2014 1:03 PM ET via RheumReports RheumReports

RACAT is a double-blind, non-inferiority trial of 353 patients who were randomized to etanercept plus methotrexate or a triple regimen consisting of methotrexate, hydroxychloroquine and sulfasalazine. After 24 weeks of treatment, patients not achieving a DAS improvement of 1.2 were switched in a blinded fashion to the other therapy.

Cost analyses were performed using Quality Adjusted Life Years (QALYs). These were estimated every 24 weeks utilizing US societal values from the EQ-5D instrument. Incremental cost-effectiveness ratios were calculated assuming intention-to-treat and presented during this plenary session.

Results showed that etanercept offered only marginally more accumulated QALYs over triple therapy, but with greater accumulation of drug costs. This translated to incremental cost-effectiveness ratios for etanerecept vs. triple therapy of $2.7 million/QALY gained over 24 weeks and $0.95 million/QALY over 48 weeks.

The large additional cost of etanercept provided very small benefits over triple therapy. It was only cost effective only after triple therapy failure. Controversially (but appropriately?), the authors commented that if triple therapy was used first, billions of dollars could be saved. This money coud be  used to further improve health outcomes using other intervention strategies.


Share This Report


About the Author

Dr. Stephanie Keeling
Dr. Stephanie Keeling

Dr. Stephanie Keeling is an Associate Professor at the University of Alberta. Her research interests include lupus and connective tissue disorders.

View Full Bio

Trending Reports From ACR 2014